ASCO 2024: Sanofi’s Sarclisa looks to gain an edge in multiple myeloma
04 Jun 2024
Preview
Source: Pharmaceutical Technology
Sarclisa is a CD38-directed cytolytic human monoclonal antibody that received its first FDA approval for the treatment of adults with previously multiple myeloma. Credits: nitpicker / Shutterstock.
Soon after Sanofi announced that the US Food and Drug Administration (FDA) accepted its supplemental biologics licence application (sBLA) for priority review, the global pharma company announced positive results for the Phase III study of its Sarclisa (isatuximab) combination therapy for the treatment of multiple myeloma (MM).
Recommended Buyer's Guides
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Leading Guide to Compliance Software for the Pharmaceutical Industry
Preview
Source: Pharmaceutical Technology
Buyer's Guide
Top Guide for Drug Delivery Systems
The results, which were shared at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from 31 May to 4 June, reported that Sarclisa in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) reduced the risk of disease progression or death by 40% compared to treatment with the VRd active comparator arm.
The randomised, multi-centre, open-label Phase III IMROZ study (NCT03319667) evaluated the treatment in 446 patients with newly diagnosed, transplant-ineligible MM. The study’s primary endpoint of progression-free survival (PFS) was met, with the estimated PFS at 60 months recorded at 63.2% in the treatment group versus 45.2% in the comparator arm. However, the regimen has not yet reached its trial median PFS.
The key secondary endpoints of IMROZ were complete response rate (CR), minimal residual disease (MRD) negativity rate for patients with a complete response, very good partial response (VGPR) or better rate, and overall survival (OS). Of the patients treated with Sarclisa/VRd, 74.7% achieved a CR and 55.5% achieved an MRD negativity rate, with 46.8% of patients sustaining MRD for at least 12 months. Comparatively, in the VRd active comparator group, 64.1% of patients achieved CR and 40.9% of patients achieved MRD negative CR, with 24.3% of patients sustaining MRD for the same 12-month period.
See Also:ASCO 2024: Alligator shares positive data for pancreatic cancer drug
Preview
Source: Pharmaceutical Technology
Philogen and Sun Pharma seek EMA approval for melanoma therapy
Preview
Source: Pharmaceutical Technology
Sarclisa demonstrated a consistent safety and tolerability profile, with no new safety signals.
Sarclisa, a CD38-directed cytolytic human monoclonal antibody, was first approved as a combination treatment for adults with MM in 2021. According to GlobalData’s consensus forecasts, The therapy is anticipated to generate global sales of $887m in 2030.
GlobalData is the parent company of Pharmaceutical Technology.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.